Prescription fill patterns for benzodiazepine and opioid drugs during the COVID-19 pandemic in the United States
COVID-19 and resulting mitigation measures in the United States (US) brought about limited access to medical care that has been linked to increases in mental health problems, excessive substance use, and drug overdoses. The increase in co-prescription of benzodiazepines and opioids may indicate popu...
Gespeichert in:
| Veröffentlicht in: | Drug and alcohol dependence 2021-12, Vol.229 (Pt A), p.109176-109176, Article 109176 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 109176 |
|---|---|
| container_issue | Pt A |
| container_start_page | 109176 |
| container_title | Drug and alcohol dependence |
| container_volume | 229 |
| creator | de Dios, Constanza Fernandes, Brisa S. Whalen, Kristine Bandewar, Shruti Suchting, Robert Weaver, Michael F. Selvaraj, Sudhakar |
| description | COVID-19 and resulting mitigation measures in the United States (US) brought about limited access to medical care that has been linked to increases in mental health problems, excessive substance use, and drug overdoses. The increase in co-prescription of benzodiazepines and opioids may indicate population-level changes in health behaviors that can be exacerbated by limited access, hence necessitating the tracking of these drugs during COVID-19. We evaluated the impact of the declaration of COVID-19 as a US national emergency on prescription patterns in 2020.
Prescriptions of benzodiazepines and opioids were analyzed using data aggregated on a weekly basis across 38 states over the January 2019-December 2020 period. Data were from Bamboo Health Prescription Drug Monitoring Program and covered all individuals regardless of insurance status. Generalized additive models estimated the effects of the March 13, 2020 declaration on proportion of prescriptions to all controlled substances by comparing volumes before to after the week of March 13 in 2020 (range: January 27-May 24) and comparing this trend to its 2019 counterpart.
When comparing the January 27-March 9 period to the March 16-May 24 period in 2020, there was a statistically significant 2.0% increase in the proportion of benzodiazepine dispensations to all controlled substances, and a significant 1.7% mean decrease in proportion of opioid dispensations to all controlled substances. A significant return approaching pre-declaration levels was observed only for opioids (beginning week of May 18, 2020).
The results suggest significant impacts of the COVID-19 pandemic on dispensations of benzodiazepines and opioids across the US. Continued monitoring of prescription trends and maintenance of adequate and accessible access to mental healthcare are important for understanding public health crises related to substance use.
•COVID-19 may disrupt physical and mental health.•Monitoring prescriptions of controlled substances can help assess disruptions.•Benzodiazepine fills increased after the week of March 13, 2020.•Fills for opioids decreased after the week of March 13, 2020.•Access to mental healthcare is needed during and after COVID-19. |
| doi_str_mv | 10.1016/j.drugalcdep.2021.109176 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8595244</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0376871621006712</els_id><sourcerecordid>2623039443</sourcerecordid><originalsourceid>FETCH-LOGICAL-c507t-bbe074275f996b7daaf09da47888a8d97d412966e83080aaf64a68fb6c34fd633</originalsourceid><addsrcrecordid>eNqFkV1vFCEUhonR2LX6FwyJN97MCjMsHzcmuvWjSZM20XpLGDizZTMLIzBN7K-X7daqvSk3JLzPeTnnvAhhSpaUUP5uu3Rp3pjROpiWLWlpfVZU8CdoQaVQDSGMP0UL0gneSEH5EXqR85bUwxV5jo46JolkXC7QdJEg2-Sn4mPAgx9HPJlSIIWMh5hwD-EmOm9uYPIBsAkOx8lH7_C-g4zdnHzY4HIFeH3-4_SkoaoaBAc7b7EPt8Jl8AUc_lZMgfwSPRvMmOHV3X2MLj9_-r7-2pydfzldfzhr7IqI0vQ9EMFasRqU4r1wxgxEOcOElNJIp4RjtFWcg-yIJFXlzHA59Nx2bHC8647R-4PvNPc7cBZCSWbUU_I7k37paLz-Xwn-Sm_itZYrtWoZqwZv7wxS_DlDLnrns4VxNAHinHXLCa1rFJRU9M0DdBvnFOp4lWo70qnqVyl5oGyKOScY7puhRO9j1Vv9N1a9j1UfYq2lr_8d5r7wT44V-HgAoK702kPS2XoIFpxPYIt20T_-y28Twboj</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2623039443</pqid></control><display><type>article</type><title>Prescription fill patterns for benzodiazepine and opioid drugs during the COVID-19 pandemic in the United States</title><source>MEDLINE</source><source>Applied Social Sciences Index & Abstracts (ASSIA)</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>de Dios, Constanza ; Fernandes, Brisa S. ; Whalen, Kristine ; Bandewar, Shruti ; Suchting, Robert ; Weaver, Michael F. ; Selvaraj, Sudhakar</creator><creatorcontrib>de Dios, Constanza ; Fernandes, Brisa S. ; Whalen, Kristine ; Bandewar, Shruti ; Suchting, Robert ; Weaver, Michael F. ; Selvaraj, Sudhakar</creatorcontrib><description>COVID-19 and resulting mitigation measures in the United States (US) brought about limited access to medical care that has been linked to increases in mental health problems, excessive substance use, and drug overdoses. The increase in co-prescription of benzodiazepines and opioids may indicate population-level changes in health behaviors that can be exacerbated by limited access, hence necessitating the tracking of these drugs during COVID-19. We evaluated the impact of the declaration of COVID-19 as a US national emergency on prescription patterns in 2020.
Prescriptions of benzodiazepines and opioids were analyzed using data aggregated on a weekly basis across 38 states over the January 2019-December 2020 period. Data were from Bamboo Health Prescription Drug Monitoring Program and covered all individuals regardless of insurance status. Generalized additive models estimated the effects of the March 13, 2020 declaration on proportion of prescriptions to all controlled substances by comparing volumes before to after the week of March 13 in 2020 (range: January 27-May 24) and comparing this trend to its 2019 counterpart.
When comparing the January 27-March 9 period to the March 16-May 24 period in 2020, there was a statistically significant 2.0% increase in the proportion of benzodiazepine dispensations to all controlled substances, and a significant 1.7% mean decrease in proportion of opioid dispensations to all controlled substances. A significant return approaching pre-declaration levels was observed only for opioids (beginning week of May 18, 2020).
The results suggest significant impacts of the COVID-19 pandemic on dispensations of benzodiazepines and opioids across the US. Continued monitoring of prescription trends and maintenance of adequate and accessible access to mental healthcare are important for understanding public health crises related to substance use.
•COVID-19 may disrupt physical and mental health.•Monitoring prescriptions of controlled substances can help assess disruptions.•Benzodiazepine fills increased after the week of March 13, 2020.•Fills for opioids decreased after the week of March 13, 2020.•Access to mental healthcare is needed during and after COVID-19.</description><identifier>ISSN: 0376-8716</identifier><identifier>EISSN: 1879-0046</identifier><identifier>DOI: 10.1016/j.drugalcdep.2021.109176</identifier><identifier>PMID: 34808468</identifier><language>eng</language><publisher>Ireland: Elsevier B.V</publisher><subject>Analgesics, Opioid - therapeutic use ; Bamboo ; Behavior change ; Benzodiazepines ; Controlled Substances ; Coronavirus-19 ; Coronaviruses ; COVID-19 ; Drug development ; Drug Prescriptions ; Drug use ; Drugs ; Generalized additive models ; Health behavior ; Health care ; Health care access ; Health insurance ; Health problems ; Health services ; Humans ; Mental disorders ; Mental health ; Mitigation ; Narcotics ; Opioids ; Overdose ; Overdoses ; Pandemics ; Prescription drugs ; Public health ; SARS-CoV-2 ; Short Communication ; Statistical analysis ; Substance abuse ; Substance use ; Telemedicine ; Therapeutic drug monitoring ; Tracking ; United States - epidemiology</subject><ispartof>Drug and alcohol dependence, 2021-12, Vol.229 (Pt A), p.109176-109176, Article 109176</ispartof><rights>2021 Elsevier B.V.</rights><rights>Copyright © 2021 Elsevier B.V. All rights reserved.</rights><rights>Copyright Elsevier Science Ltd. Dec 1, 2021</rights><rights>2021 Elsevier B.V. All rights reserved. 2021 Elsevier B.V.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c507t-bbe074275f996b7daaf09da47888a8d97d412966e83080aaf64a68fb6c34fd633</citedby><cites>FETCH-LOGICAL-c507t-bbe074275f996b7daaf09da47888a8d97d412966e83080aaf64a68fb6c34fd633</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.drugalcdep.2021.109176$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,780,784,885,3548,27923,27924,30998,45994</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34808468$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>de Dios, Constanza</creatorcontrib><creatorcontrib>Fernandes, Brisa S.</creatorcontrib><creatorcontrib>Whalen, Kristine</creatorcontrib><creatorcontrib>Bandewar, Shruti</creatorcontrib><creatorcontrib>Suchting, Robert</creatorcontrib><creatorcontrib>Weaver, Michael F.</creatorcontrib><creatorcontrib>Selvaraj, Sudhakar</creatorcontrib><title>Prescription fill patterns for benzodiazepine and opioid drugs during the COVID-19 pandemic in the United States</title><title>Drug and alcohol dependence</title><addtitle>Drug Alcohol Depend</addtitle><description>COVID-19 and resulting mitigation measures in the United States (US) brought about limited access to medical care that has been linked to increases in mental health problems, excessive substance use, and drug overdoses. The increase in co-prescription of benzodiazepines and opioids may indicate population-level changes in health behaviors that can be exacerbated by limited access, hence necessitating the tracking of these drugs during COVID-19. We evaluated the impact of the declaration of COVID-19 as a US national emergency on prescription patterns in 2020.
Prescriptions of benzodiazepines and opioids were analyzed using data aggregated on a weekly basis across 38 states over the January 2019-December 2020 period. Data were from Bamboo Health Prescription Drug Monitoring Program and covered all individuals regardless of insurance status. Generalized additive models estimated the effects of the March 13, 2020 declaration on proportion of prescriptions to all controlled substances by comparing volumes before to after the week of March 13 in 2020 (range: January 27-May 24) and comparing this trend to its 2019 counterpart.
When comparing the January 27-March 9 period to the March 16-May 24 period in 2020, there was a statistically significant 2.0% increase in the proportion of benzodiazepine dispensations to all controlled substances, and a significant 1.7% mean decrease in proportion of opioid dispensations to all controlled substances. A significant return approaching pre-declaration levels was observed only for opioids (beginning week of May 18, 2020).
The results suggest significant impacts of the COVID-19 pandemic on dispensations of benzodiazepines and opioids across the US. Continued monitoring of prescription trends and maintenance of adequate and accessible access to mental healthcare are important for understanding public health crises related to substance use.
•COVID-19 may disrupt physical and mental health.•Monitoring prescriptions of controlled substances can help assess disruptions.•Benzodiazepine fills increased after the week of March 13, 2020.•Fills for opioids decreased after the week of March 13, 2020.•Access to mental healthcare is needed during and after COVID-19.</description><subject>Analgesics, Opioid - therapeutic use</subject><subject>Bamboo</subject><subject>Behavior change</subject><subject>Benzodiazepines</subject><subject>Controlled Substances</subject><subject>Coronavirus-19</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>Drug development</subject><subject>Drug Prescriptions</subject><subject>Drug use</subject><subject>Drugs</subject><subject>Generalized additive models</subject><subject>Health behavior</subject><subject>Health care</subject><subject>Health care access</subject><subject>Health insurance</subject><subject>Health problems</subject><subject>Health services</subject><subject>Humans</subject><subject>Mental disorders</subject><subject>Mental health</subject><subject>Mitigation</subject><subject>Narcotics</subject><subject>Opioids</subject><subject>Overdose</subject><subject>Overdoses</subject><subject>Pandemics</subject><subject>Prescription drugs</subject><subject>Public health</subject><subject>SARS-CoV-2</subject><subject>Short Communication</subject><subject>Statistical analysis</subject><subject>Substance abuse</subject><subject>Substance use</subject><subject>Telemedicine</subject><subject>Therapeutic drug monitoring</subject><subject>Tracking</subject><subject>United States - epidemiology</subject><issn>0376-8716</issn><issn>1879-0046</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>7QJ</sourceid><recordid>eNqFkV1vFCEUhonR2LX6FwyJN97MCjMsHzcmuvWjSZM20XpLGDizZTMLIzBN7K-X7daqvSk3JLzPeTnnvAhhSpaUUP5uu3Rp3pjROpiWLWlpfVZU8CdoQaVQDSGMP0UL0gneSEH5EXqR85bUwxV5jo46JolkXC7QdJEg2-Sn4mPAgx9HPJlSIIWMh5hwD-EmOm9uYPIBsAkOx8lH7_C-g4zdnHzY4HIFeH3-4_SkoaoaBAc7b7EPt8Jl8AUc_lZMgfwSPRvMmOHV3X2MLj9_-r7-2pydfzldfzhr7IqI0vQ9EMFasRqU4r1wxgxEOcOElNJIp4RjtFWcg-yIJFXlzHA59Nx2bHC8647R-4PvNPc7cBZCSWbUU_I7k37paLz-Xwn-Sm_itZYrtWoZqwZv7wxS_DlDLnrns4VxNAHinHXLCa1rFJRU9M0DdBvnFOp4lWo70qnqVyl5oGyKOScY7puhRO9j1Vv9N1a9j1UfYq2lr_8d5r7wT44V-HgAoK702kPS2XoIFpxPYIt20T_-y28Twboj</recordid><startdate>20211201</startdate><enddate>20211201</enddate><creator>de Dios, Constanza</creator><creator>Fernandes, Brisa S.</creator><creator>Whalen, Kristine</creator><creator>Bandewar, Shruti</creator><creator>Suchting, Robert</creator><creator>Weaver, Michael F.</creator><creator>Selvaraj, Sudhakar</creator><general>Elsevier B.V</general><general>Elsevier Science Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QJ</scope><scope>7TK</scope><scope>7U7</scope><scope>C1K</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20211201</creationdate><title>Prescription fill patterns for benzodiazepine and opioid drugs during the COVID-19 pandemic in the United States</title><author>de Dios, Constanza ; Fernandes, Brisa S. ; Whalen, Kristine ; Bandewar, Shruti ; Suchting, Robert ; Weaver, Michael F. ; Selvaraj, Sudhakar</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c507t-bbe074275f996b7daaf09da47888a8d97d412966e83080aaf64a68fb6c34fd633</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Analgesics, Opioid - therapeutic use</topic><topic>Bamboo</topic><topic>Behavior change</topic><topic>Benzodiazepines</topic><topic>Controlled Substances</topic><topic>Coronavirus-19</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>Drug development</topic><topic>Drug Prescriptions</topic><topic>Drug use</topic><topic>Drugs</topic><topic>Generalized additive models</topic><topic>Health behavior</topic><topic>Health care</topic><topic>Health care access</topic><topic>Health insurance</topic><topic>Health problems</topic><topic>Health services</topic><topic>Humans</topic><topic>Mental disorders</topic><topic>Mental health</topic><topic>Mitigation</topic><topic>Narcotics</topic><topic>Opioids</topic><topic>Overdose</topic><topic>Overdoses</topic><topic>Pandemics</topic><topic>Prescription drugs</topic><topic>Public health</topic><topic>SARS-CoV-2</topic><topic>Short Communication</topic><topic>Statistical analysis</topic><topic>Substance abuse</topic><topic>Substance use</topic><topic>Telemedicine</topic><topic>Therapeutic drug monitoring</topic><topic>Tracking</topic><topic>United States - epidemiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>de Dios, Constanza</creatorcontrib><creatorcontrib>Fernandes, Brisa S.</creatorcontrib><creatorcontrib>Whalen, Kristine</creatorcontrib><creatorcontrib>Bandewar, Shruti</creatorcontrib><creatorcontrib>Suchting, Robert</creatorcontrib><creatorcontrib>Weaver, Michael F.</creatorcontrib><creatorcontrib>Selvaraj, Sudhakar</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Applied Social Sciences Index & Abstracts (ASSIA)</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Drug and alcohol dependence</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>de Dios, Constanza</au><au>Fernandes, Brisa S.</au><au>Whalen, Kristine</au><au>Bandewar, Shruti</au><au>Suchting, Robert</au><au>Weaver, Michael F.</au><au>Selvaraj, Sudhakar</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prescription fill patterns for benzodiazepine and opioid drugs during the COVID-19 pandemic in the United States</atitle><jtitle>Drug and alcohol dependence</jtitle><addtitle>Drug Alcohol Depend</addtitle><date>2021-12-01</date><risdate>2021</risdate><volume>229</volume><issue>Pt A</issue><spage>109176</spage><epage>109176</epage><pages>109176-109176</pages><artnum>109176</artnum><issn>0376-8716</issn><eissn>1879-0046</eissn><abstract>COVID-19 and resulting mitigation measures in the United States (US) brought about limited access to medical care that has been linked to increases in mental health problems, excessive substance use, and drug overdoses. The increase in co-prescription of benzodiazepines and opioids may indicate population-level changes in health behaviors that can be exacerbated by limited access, hence necessitating the tracking of these drugs during COVID-19. We evaluated the impact of the declaration of COVID-19 as a US national emergency on prescription patterns in 2020.
Prescriptions of benzodiazepines and opioids were analyzed using data aggregated on a weekly basis across 38 states over the January 2019-December 2020 period. Data were from Bamboo Health Prescription Drug Monitoring Program and covered all individuals regardless of insurance status. Generalized additive models estimated the effects of the March 13, 2020 declaration on proportion of prescriptions to all controlled substances by comparing volumes before to after the week of March 13 in 2020 (range: January 27-May 24) and comparing this trend to its 2019 counterpart.
When comparing the January 27-March 9 period to the March 16-May 24 period in 2020, there was a statistically significant 2.0% increase in the proportion of benzodiazepine dispensations to all controlled substances, and a significant 1.7% mean decrease in proportion of opioid dispensations to all controlled substances. A significant return approaching pre-declaration levels was observed only for opioids (beginning week of May 18, 2020).
The results suggest significant impacts of the COVID-19 pandemic on dispensations of benzodiazepines and opioids across the US. Continued monitoring of prescription trends and maintenance of adequate and accessible access to mental healthcare are important for understanding public health crises related to substance use.
•COVID-19 may disrupt physical and mental health.•Monitoring prescriptions of controlled substances can help assess disruptions.•Benzodiazepine fills increased after the week of March 13, 2020.•Fills for opioids decreased after the week of March 13, 2020.•Access to mental healthcare is needed during and after COVID-19.</abstract><cop>Ireland</cop><pub>Elsevier B.V</pub><pmid>34808468</pmid><doi>10.1016/j.drugalcdep.2021.109176</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0376-8716 |
| ispartof | Drug and alcohol dependence, 2021-12, Vol.229 (Pt A), p.109176-109176, Article 109176 |
| issn | 0376-8716 1879-0046 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8595244 |
| source | MEDLINE; Applied Social Sciences Index & Abstracts (ASSIA); ScienceDirect Journals (5 years ago - present) |
| subjects | Analgesics, Opioid - therapeutic use Bamboo Behavior change Benzodiazepines Controlled Substances Coronavirus-19 Coronaviruses COVID-19 Drug development Drug Prescriptions Drug use Drugs Generalized additive models Health behavior Health care Health care access Health insurance Health problems Health services Humans Mental disorders Mental health Mitigation Narcotics Opioids Overdose Overdoses Pandemics Prescription drugs Public health SARS-CoV-2 Short Communication Statistical analysis Substance abuse Substance use Telemedicine Therapeutic drug monitoring Tracking United States - epidemiology |
| title | Prescription fill patterns for benzodiazepine and opioid drugs during the COVID-19 pandemic in the United States |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T16%3A52%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prescription%20fill%20patterns%20for%20benzodiazepine%20and%20opioid%20drugs%20during%20the%20COVID-19%20pandemic%20in%20the%20United%20States&rft.jtitle=Drug%20and%20alcohol%20dependence&rft.au=de%20Dios,%20Constanza&rft.date=2021-12-01&rft.volume=229&rft.issue=Pt%20A&rft.spage=109176&rft.epage=109176&rft.pages=109176-109176&rft.artnum=109176&rft.issn=0376-8716&rft.eissn=1879-0046&rft_id=info:doi/10.1016/j.drugalcdep.2021.109176&rft_dat=%3Cproquest_pubme%3E2623039443%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2623039443&rft_id=info:pmid/34808468&rft_els_id=S0376871621006712&rfr_iscdi=true |